ABSTRACT
Objective To investigate the toxic effect of nona-ferroso-ferric oxide(Nano-Fe_3O_4),nano-silicon dioxide(Nano- SiO_2)and single walled carbon nanotubes(SWCNTs)on the lung and mechanism in rats.Methods Fourty-nine Wistar rats were randomly divided into 7 groups,the control group,low and high dose groups of three nanomaterials.The rats were exposed by intratracheal instillation once two days for 5 weeks,and then killed by abdominal aorta bloodletting.The pathology of lung,lactate dehydrogenase(LDH),total antioxidant capacity(T-AOC),superoxide dismutase(SOD),malondialdehyde(MDA),interleukin-1(IL- l),interleukin-6(IL-6)and tumor necrosis factor-?(TNF-?)in bronchoalveolar lavage fluid(BALF)were determined.Results The fibrous tubercle and the matrix inflammation of lung tissue was found in the experimental groups.The activities of T-AOC and SOD decreased while IL-6 concentration increased significantly in the experimental groups(P
ABSTRACT
<p><b>OBJECTIVE</b>To prepare a new dosage formulation of activated carbon nanoparticles adsorbing mitomycin C (MMC-ACNP) and evaluate the beneficial effects of intraperitoneally applied MMC-ACNP as a drug delivery system for lymphatic targeting in preventing metastasis and recurrence of gastric cancer.</p><p><b>METHODS</b>MMC-ACNP was prepared. Acute toxicity after its intraperitoneal administration was evaluated. An experiment on nude mice model with transplanted human gastric cancer in 6 groups was completed to assess the effects of drugs on intra-abdominal carcinomatosis.</p><p><b>RESULTS</b>The LD50 of MMC-ACNP was 46.80 mg/kg (in terms of MMC) while that of MMC aqueous solution was 9.33 mg/kg. The toxicity of MMC-ACNP was much less than that of the solution form. MMC-ACNP was superior to MMC aqueous solution in controlling carcinomatosis and tumor growth by intraperitoneal administration. Despite the high dose of MMC, leukopenia and thrombocytopenia were not observed in the MMC-ACNP treated group. Fine activated carbon particles adsorbing MMC entered the nuclei of tumor cells, so that the effects of the anticancer drug were reinforced.</p><p><b>CONCLUSION</b>MMC-ACNP gives a good promise of clinical use due to its advantages such as high selectivity and low toxicity.</p>
Subject(s)
Animals , Female , Humans , Male , Mice , Adenocarcinoma, Mucinous , Pathology , Antibiotics, Antineoplastic , Pharmacology , Charcoal , Drug Carriers , Drug Delivery Systems , Injections, Intraperitoneal , Mice, Inbred BALB C , Mice, Nude , Mitomycin , Pharmacology , Nanoparticles , Neoplasm Transplantation , Stomach Neoplasms , Pathology , ThrombocytopeniaABSTRACT
<p><b>OBJECTIVE</b>To analyze the relationship between the expression of FasL, Perforin and Granzyme B and the development of acute graft versus host disease (aGVHD) after allogeneic hematopoietic stem cell transplantation (allo-HSCT).</p><p><b>METHODS</b>The peripheral blood mRNA expression of granzyme B, perforin, fasL from 17 patients after allo-HSCT was detected by competitive quantitative RT-PCR and the relationship between FasL, Granzyme B and Perforin expressions and clinical symptom of aGVHD was analyzed.</p><p><b>RESULTS</b>The expression level of Granzyme B, Perforin and FasL was 4.6 +/- 0.2, 4.5 +/- 0.1, 1.4 +/- 0.1 before aGVHD occurrence respectively, and was 98.7 +/- 2.5, 91.8 +/- 3.4, 61.5 +/- 2.2, after the occurrence in 14 patients (P < or = 0.05). Over expressions of Granzyme B, Perforin, and FasL during acute GVHD were detected in 13 of 14, 12 of 14, and 12 of 14 patients respectively. The upregulated expressions occurred prior to clinical symptom of aGVHD.</p><p><b>CONCLUSION</b>The expressions of Granzyme B, Perforin, and FasL were significantly high in patients with acute aGVHD. Monitoring of the expressions, might predict the occurrence of clinical aGVHD and it severity and prognosis.</p>